2227996-00-9
2227996-00-9 结构式
常见问题列表
IC50: 609 nM (NRP1-a1 and NRP1-b) Kd: 1.32 μM (NRP1-b1)
EG01377 (3-30 μM; 30 minutes) inhibits vascular endothelial growth factor A (VEGF-A) stimulated tyrosine phosphorylation of VEGF-R2/KDR.
EG01377 (30 μM) is able to significantly reduce HUVEC cell migration in response to VEGFA.
EG01377 (30 μM; 5 days) can delay the VEGF-induced wound closure.
EG01377 (30 μM) reduces network area, length, and branching points.
EG01377 (30 μM; 7 days) reduces VEGF-induced angiogenesis.
EG01377 (30 μM; 7 days) in combination with VEGFA reduces A375P (malignant melanoma) spheroid outgrowth.
EG01377 (500 nM; 2 hours) blocks the production of transforming growth factor beta (TGFβ) by Nrp1
+
regulatory T-cell SMAD3/AKT (Tregs) in the presence of tumor cell-derived factors.
Western Blot Analysis
| Cell Line: | Human umbilical vein endothelial cells (HUVECs) |
| Concentration: | 3, 10, 30 μM |
| Incubation Time: | 30 minutes |
| Result: | Inhibited VEGF-A stimulated tyrosine phosphorylation of VEGF-R2/KDR with an IC 50 of 30 μM. |
EG01377 (2 mg/kg; i.v.) exhibits an encouraging half-life of 4.29 h, sufficient to sustain once per day dosing in mice.
| Animal Model: | 6–8 week-old BABL/c female mice |
| Dosage: | 2 mg/kg (Pharmacokinetic Analysis) |
| Administration: | I.v. administration |
| Result: | The half time (T 1/2 ) of 4.29 h. |